What is NDC 51662-1317?

51662-1317 is the product NDC for 6% Hetastarch In 0.9% Sodium Chloride, Hetastarch 6 g/100mL injection, solution, listed with the FDA by HF Acquisition Co LLC, DBA HealthFirst. It has 2 package NDCs, shown above in 10- and 11-digit form.

HF Acquisition Co LLC, DBA HealthFirst, NDC labeler code 51662. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for 6% Hetastarch In 0.9% Sodium Chloride?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

6% Hetastarch In 0.9% Sodium Chloride NDC 51662-1317

NDC codes

FDA NDC Directory

Product NDC (as listed)51662-1317Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51662-1317Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51662-1317-1	51662131701	500 mL in 1 CONTAINER (51662-1317-1)Marketed from Nov 26, 2018
51662-1317-3	51662131703	12 CONTAINER in 1 CASE (51662-1317-3) / 500 mL in 1 CONTAINER (51662-1317-2)Marketed from Nov 26, 2018

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): 6% Hetastarch In 0.9% Sodium Chloride
Generic name (nonproprietary): 6% hetastarch in 0.9% sodium chloride
Active ingredients: Hetastarch — 6 g/100mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: HF Acquisition Co LLC, DBA HealthFirstNDC labeler code 51662
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application BA 740193
Marketing start: Nov 26, 2018
Listing expires: Dec 31, 2026
Other FDA classes: Increased Intravascular Volume (Physiologic effect)Osmotic Activity (Mechanism)Starch (Chemical structure)
Identifiers: Product ID 51662-1317_101e9d56-6d64-1bf0-e063-6394a90a22f7SPL ID 101e9d56-6d64-1bf0-e063-6394a90a22f7SPL set ID 7b97c681-4514-c544-e053-2991aa0a3d78RxCUI 310757UNII 875Y4127EA
Pharmacologic class: Plasma Volume Expander

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N451662131701 followed by a unit qualifier and the quantity

Package 51662-1317-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 29, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

6% Hetastarch in 0.9% Sodium Chloride Injection is indicated in the treatment of hypovolemia when plasma volume expansion is desired. It is not a substitute for blood or plasma. The adjunctive use of 6% Hetastarch in 0.9% Sodium Chloride Injection in leukapheresis has also been shown to be safe and efficacious in improving the harvesting and increasing the yield of granulocytes by centrifugal means.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 51662-1317

What is NDC 51662-1317?: 51662-1317 is the product NDC for 6% Hetastarch In 0.9% Sodium Chloride, Hetastarch 6 g/100mL injection, solution, listed with the FDA by HF Acquisition Co LLC, DBA HealthFirst. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: 6% Hetastarch In 0.9% Sodium Chloride.
What is the active ingredient?: Hetastarch.
Who is the labeler?: HF Acquisition Co LLC, DBA HealthFirst, NDC labeler code 51662. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for 6% Hetastarch In 0.9% Sodium Chloride?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other NDCs under BA 740193

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BA 740193
Product	Strength	Form · route	Labeler	Product NDC
Hetastarch in Sodium Chloridehetastarch	Hetastarch 6 g/100mL	Injection, SolutionIntravenous	Hospira, Inc.	0409-7248